Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study

AIDS

Volumn 22, Issue 16, 2008, Pages 2187-2198

  Cozzi Lepri, Alessandro ^a   Phillips, Andrew N ^a   Clotet, Bonaventura ^b   Mocroft, Amanda ^a   Ruiz, Lidia ^b   Kirk, Ole ^c   Lazzarin, Adriano ^e   Wiercinska Drapalo, Alicja ^f   Karlsson, Anders ^g   Lundgren, Jens D ^c,d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b IrsiCaixa Foundation   (Spain)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Centre for Viral Diseases at KMA   (Denmark)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical progression; Drug resistance mutations; Virological failure

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; EPIDEMIOLOGIC METHODS; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 55249094827     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328310e04f     Document Type: Article

References (33)

1. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
2. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279:1977-1983.
3. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
4. Mayers DL. Drug-resistant HIV-1: the virus strikes back. JAMA 1998; 279:2000-2002.
5. Lundgren JD, Mocroft A. The impact of antiretroviral therapy on AIDS and survival. J HIV Ther 2006; 11:36-38.
6. Schneider MF, Gange SJ, Williams CM, Anastos K, Greenblatt RM, Kingsley L, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 2005; 19:2009-2018.
7. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, et al., Collaborative Group for Clinical Use of HIV Genotype Resistance Test (GRT) at National Institute for Infectious Diseases Lazzaro Spallanzani. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19:1081-1089.
8. Di Giambenedetto S, Colafigli M, Pinnetti C, Bacarelli A, Cingolani A, Tamburrini E, et al. Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. AIDS Res Hum Retroviruses 2008; 24:149-154.
9. Ormaasen V, Sandvik L, Asjo B, Holberg-Petersen M, Gaarder PI, Bruun JN. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy. HIV Med 2004; 5:400-406.
10. Napravnick S, Keys J, Stalzer B, Eron JJ. Extensive HIV-1 antiretroviral drug class resistance is associated with inferior virological and clinical outcomes [abstract 59]. Antivir Ther 2007; 12 (Suppl 1):S68.
11. Lohse N, Jørgensen LB, Kronborg G, Møller A, Kvinesdal B, Sørensen HT, et al., and the Danish HIV Cohort Study. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure. Antivir Ther 2007; 12: 909-917.
12. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 2004; 18:1539-1548.
13. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother 2005; 55:413-416.
14. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.1. PLoS Med 2006; 3:e356.
15. Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf M, Peng G, Xiang Y, et al., Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007; 8:357-370.
16. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347.
17. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, et al., UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19:487-494.
18. Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, et al. Drug-class-wide resistance to antiretroviral in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Collaborative Group for Clinical Use of HIV Genotype Resistance Test. Antivir Ther 2006; 11:553-560.
19. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS 2007; 21:825-834.
20. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, et al., Writing Committee, British HIV Association. British HIV Association (BHIVA) Guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
21. Sax PE. Updated DHHS treatment guidelines. AIDS Clin Care 2006; 18:105.
22. Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WW, et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004; 190:285-292.
23. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
24. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14:125-130.
25. Markowitz M. Resistance, fitness, adherence, and potency: mapping the paths to virologic failure. JAMA 2000; 283: 250-251.
26. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14:23-28.
27. Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, et al. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. J Virol 2003; 77:6041-6049.
28. Deeks SG, Martin JN, Sinclair E, Harris J, Neilands TB, Maecker HT, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004; 189:312-321.
29. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79:14169-14178.
30. Stoddart CA, Liegler TJ, Mammano F, Linquist-Stepps VD, Hayden MS, Deeks SG, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001; 7:712-718.
31. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, et al. Increased froiess of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13:2349-2359.
32. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, et al., EuroSIDA Study Group. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combinant antiretroviral therapy regimen. AIDS 2007; 21:721-732.
33. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al., Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.